News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $45.90. The company recently reported quarterly EPS of -$0.52, exceeding the consensus estimate. Institutional investors have also increased their holdings in the company.
Cogent Biosciences reported strong second-quarter 2026 financial results and significant business highlights, including progress toward potential FDA approvals for bezuclastinib for GIST and NonAdvSM later this year. The company also announced the successful onboarding of a cross-functional customer-facing team and a robust pro forma …
Cogent Biosciences (COGT) has filed a prospectus supplement for an at-the-market (ATM) stock program, allowing it to offer and sell up to $400 million of its common stock. This program uses an existing automatic shelf registration statement and permits sales through Guggenheim Securities, LLC. …
Cogent Biosciences (NASDAQ: COGT) has provided updates on its financial runway and the FDA timelines for its drug bezuclastinib. The company reported a net loss of $96.4 million for Q2 2026, widening from the previous year, but has $792.3 million in cash, cash equivalents, …
Cogent Biosciences is scheduled to report second-quarter earnings, with investors keenly watching for updates on its commercial launch preparations for bezuclastinib, its lead drug candidate, ahead of potential FDA approvals later this year. The company is transitioning from a clinical-stage to a marketed-drug business …
Cogent Biosciences (COGT) reported a widened net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, driven by increased R&D and G&A expenses. The company has sufficient cash runway into late 2028 and is approaching key FDA PDUFA dates …
Cogent Biosciences reported a wider net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, primarily due to increased R&D and G&A expenses. Despite this, the company is advancing towards potential FDA approvals for bezuclastinib in GIST (November 30, …
Cogent Biosciences reported its Q2 2026 financial results, highlighting significant progress for its drug bezuclastinib with FDA New Drug Applications submitted for GIST and systemic mastocytosis. The company anticipates FDA decisions for GIST by November 30, 2026, and for NonAdvSM by December 30, 2026. …
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Cogent Biosciences (NASDAQ:COGT) by 59.6% in the second quarter, selling 194,697 shares but retaining 131,775 shares valued at approximately $5.1 million. Despite this sale, analyst sentiment for Cogent Biosciences remains positive with a …
Assenagon Asset Management S.A. significantly increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 387.7% in the second quarter, now holding 1.44 million shares valued at $55.8 million. Other major institutional investors like Deerfield Management, RTW Investments, Vanguard, and T. Rowe Price also expanded …
Cogent Biosciences (NASDAQ: COGT) has significantly outperformed the market over the past five years, with an annualized return of 40.76%. An initial investment of $100 in COGT stock five years ago would now be worth $584.69. This article highlights the power of compounded returns …
This article analyzes Cogent Biosciences, Inc.'s financial performance and future prospects, focusing on its path to breakeven. Analysts project the company to reach profitability within two years, with significant revenue growth expected in the coming years. The piece also delves into the risks and …
Cogent Biosciences (COGT) shares rose 10.2% due to renewed investor optimism regarding its drug bezuclastinib and a busy regulatory schedule. The company recently submitted its third NDA for bezuclastinib in six months, with decisions for other applications expected later in 2026. Cogent is also …
This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) focusing on its behavioral patterns and institutional flows. Key findings indicate a near-term neutral sentiment amidst mid and long-term strength, with a notable 83.7:1 risk-reward setup. The analysis provides specific institutional trading strategies, including position, momentum …
Vanguard Capital Management LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.08% in Cogent Biosciences Inc (COGT), amounting to 8,691,589 shares. The filing indicates that Vanguard holds sole voting power over 1,279,259 shares and sole dispositive power over all 8,691,589 shares, …
This article provides a comprehensive stock analysis of Cogent Biosciences Inc (COGT) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and high institutional ownership. The valuation is considered fairly valued, and analysts have issued a "Buy" rating with a target price …
This article analyzes market sentiment for Cogent Biosciences (COGT) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" analyst consensus with 16 analysts, a 9.6% rising short float, and a bullish options flow with a 0.27 Put/Call ratio. …
This article provides a financial health analysis of Cogent Biosciences Inc (COGT) by TradingKey, focusing on its profitability and balance sheet. The company has a current financial score of 6.80, ranking 205 out of 384 in its industry, indicating robust financial status but low …
Cogent Biosciences Inc (COGT) has achieved an institutional shareholding score of 10.00, placing it first among 386 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 14.34% quarter-over-quarter, reaching 102.81%. Steven Cohen is the largest institutional shareholder, holding …
This article provides historical dividend and stock split information for Cogent Biosciences Inc (COGT). It notes that COGT has distributed $0.00 in dividends over the past five years and details multiple 4-for-1 merger-related stock splits that occurred on November 6, 2020. The article also …
This article from TradingKey provides a revenue breakdown for Cogent Biosciences Inc (COGT). It notes that relevant revenue data by business segment and region for FY2021 has not yet been disclosed by the company, though it lists the United States as a region with …
This article provides a detailed breakdown of Cogent Biosciences Inc.'s (COGT) shareholder structure, including major shareholders, shareholder types by proportion, and institutional holdings over several quarters. It lists top institutional investors like Fidelity, BlackRock, and Deerfield Management, alongside their proportional holdings and changes. The …
Cogent Biosciences Inc. (COGT) closed at $39.76, down 1.19%. The company has strong fundamentals and high growth potential, with its valuation considered fairly priced within the Biotechnology & Medical Research industry. Analysts currently rate the stock as a "Buy" with a target price of …
This article provides a valuation analysis of Cogent Biosciences Inc (COGT) as of July 24, 2026. The company currently has a valuation score of 8.84, ranking 89th in its industry, and a P/E ratio of -18.40. Key metrics like P/B, P/CF, and specific P/E …
This article provides an algorithmic analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting near-term strong sentiment potentially leading to mid-term neutrality and long-term positive bias. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and risk/reward parameters for …
This page provides a risk profile for the Cogent Biosciences, Inc. 1.625% 15-NOV-2031 bond, identified by FINRA COGT6232219. It offers an overview of the bond, focusing on credit risk assessment and key metrics for risk analysis. The platform also promises access to exclusive analyst …
This article provides a coupon profile for the Cogent Biosciences, Inc. bond COGT6232219, which has a 1.625% interest rate maturing on November 15, 2031. It details the current coupon rate of 1.63% and announces that the next payment is scheduled for November 16, 2026. …
Search by ticker symbol or company name and select a result to open its chart.